Needham Reiterates Buy on Acadia Pharmaceuticals, Maintains $35 Price Target

Benzinga · 4d ago
Needham analyst Ami Fadia reiterates Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintains $35 price target.